(MENAFN- EIN Presswire)
Pulmonary Drugs market - Exclusive Report by 360iResearch
The Global Pulmonary Drugs Market to grow from USD 72.73 billion in 2022 to USD 136.27 billion by 2030, at a CAGR of 8.16%.
PUNE, MAHARASHTRA, INDIA, November 10, 2023 /EINPresswire / -- The "Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Global Forecast 2023-2030" report has been added to 360iResearch's offering.
The Global Pulmonary Drugs Market to grow from USD 72.73 billion in 2022 to USD 136.27 billion by 2030, at a CAGR of 8.16%.
Request a Free Sample Report @
The pulmonary drugs market encompasses a wide range of therapeutic solutions specifically designed for the prevention, diagnosis, and treatment of respiratory diseases. Pulmonary drugs are primarily used in treating various respiratory conditions such as pneumonia, tuberculosis, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, allergic rhinitis, and other pulmonary ailments. The rising prevalence of pulmonary diseases and government initiatives to promote disease treatment have increased the need for pulmonary drugs. The improvements in reimbursement policies and favorable government approvals for pulmonary drugs also contribute to market growth. However, incidents of product recalls may limit the adoption of pulmonary drugs. The limitations associated with improper drug delivery and the development of drug resistance are also expected to create challenges in the adoption of pulmonary drugs. Moreover, The development of new biologics & targeted drugs for pulmonary disease treatment and advancements in inhaled drug delivery therapies are expected to create potential growth opportunities in the market.
End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals
In the homecare segment, patients with chronic respiratory diseases, including asthma, tuberculosis, and chronic obstructive pulmonary disease (COPD) require regular medication and management. Hospitals serve as critical centers for the treatment of acute exacerbations and severe cases of respiratory disorders. Specialty clinics cater to patients with specific respiratory conditions, including cystic fibrosis, interstitial lung diseases, and pulmonary arterial hypertension (PAH).
Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers
Hospital pharmacies are an essential distribution channel for pulmonary drugs, primarily due to their strategic location within healthcare facilities. This enables healthcare professionals to have immediate access to life-saving medications for patients with chronic and acute respiratory disorders. Online pharmacies have emerged as a convenient and cost-effective platform for purchasing pulmonary drugs. They offer advantages such as doorstep delivery, privacy, discounts, and ease of access to medications without needing a physical visit to a pharmacy store. Retail pharmacies constitute a significant distribution channel for pulmonary drugs, owing to their widespread presence and ease of access for patients.
Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases
Anticholinergic agents are a class of drugs that block the action of acetylcholine, a neurotransmitter responsible for transmitting impulses in the airways. These medications help reduce bronchoconstriction and airway secretions, making them useful for treating chronic obstructive pulmonary disease (COPD) and asthma. Anti-leukotrienes are medications that combat inflammation in the respiratory system by blocking the effects of leukotrienes, which are chemicals involved in immune responses leading to airway constriction and mucus production. They are used primarily to treat asthma, especially in patients who do not respond well to traditional treatments such as inhaled corticosteroids or beta-2 agonists. Antihistamines work by inhibiting histamine, a chemical mediator released during allergic reactions, thereby reducing allergy symptoms such as sneezing, itching, and nasal congestion. Antihistamines can be beneficial in treating asthma and chronic rhinitis associated with allergies; however, it is primarily intended for pulmonary conditions. Beta-2 agonists are pulmonary drugs that stimulate beta-2 adrenergic receptors on bronchial smooth muscle cells, causing relaxation and bronchodilation, which is essential for managing asthma and COPD symptoms. Combination drugs contain two or more different classes of medications to enhance efficacy while minimizing side effects. They are often prescribed when single-agent therapies do not provide adequate symptom control. Monoclonal antibodies are biological drugs engineered to target specific cellular pathways involved in inflammatory and immune-mediated airway diseases, such as severe asthma. Corticosteroids, both oral and inhaled, are potent anti-inflammatory agents used to treat various pulmonary disorders such as asthma and COPD.
Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis
Allergic rhinitis is an inflammatory condition that impacts the nasal passages due to exposure to allergens, including pollen, dust mites, or animal dander. The most commonly used medications for managing this condition include antihistamines, leukotriene receptor antagonists, and intranasal corticosteroids. Asthma is a chronic inflammatory respiratory disease portraying airway obstruction and bronchospasm. Depending on the severity and individual patient needs, asthma management can involve short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), or biologics. Chronic obstructive pulmonary disease (COPD) is a lung disease involving chronic bronchitis and emphysema that results in airflow obstruction. Cystic fibrosis, a genetic disorder, causes the accumulation of thick mucus in the lungs, causing chronic infections and respiratory failure. The primary treatment approach involves targeting the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein with modulators and managing symptoms using bronchodilators, antibiotics, and mucolytics. Pulmonary arterial hypertension (PAH) is a rare, severe disorder leading to high blood pressure in the arteries supplying blood to the lungs. The main classes of drugs utilized to treat PAH include endothelin receptor antagonists (ERAs), prostacyclin analogs or agonists, soluble guanylate cyclase stimulators (sGCS), and phosphodiesterase type 5 inhibitors (PDE-5i).
Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management
Prescription drugs are medications that require a prescription from a licensed healthcare professional before they can be dispensed to patients. These medications undergo rigorous testing and regulatory processes to ensure safety and efficacy before being approved by governing agencies such as the Food & Drug Administration (FDA) or the European Medicines Agency (EMA). Prescription pulmonary drugs offer targeted therapies with advanced mechanisms of action designed to address the underlying causes of respiratory diseases. Generic drugs are bioequivalent to branded drugs in dosage form, strength, route of administration, quality, performance characteristics, and intended use. These drugs enter the market after the patent expiration of their branded counterparts and are typically priced lower than the original products. The cost-effectiveness is a primary factor driving the preference for generic drugs among healthcare providers and patients who require long-term treatments or have limited financial resources.
Regional Insights:
The Americas region has a highly developed infrastructure for manufacturing of pulmonary drugs due to the presence of major market players in the area. In major countries such as the United States, Canada, and Brazil, respiratory diseases such as Chronic Obstructive Pulmonary Disease, Tuberculosis, and Asthma are prevalent among both children and adults, increasing the need for pulmonary drugs. EMEA countries, including Germany, France, Italy, Spain, and others, also have a high prevalence of respiratory disorders owing to the growing aging population, contributing to the market growth in the region. Middle-East countries such as Saudi Arabia and the UAE have invested heavily in health infrastructure improvements to address this public health concern. The Asian region is witnessing market growth due to increasing government investments in major countries such as China, India, and Japan. The market players in the region concentrate on producing affordable generics for pulmonary conditions and investing in the development of new drugs domestically.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is essential for assessing the Pulmonary Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).
Market Share Analysis:
The Market Share Analysis offers an insightful look at the current state of vendors in the Pulmonary Drugs Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.
Key Company Profiles:
The report delves into recent significant developments in the Pulmonary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Chiesi Farmaceutici S.p.A, Cipla Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Grifols, S.A., Icosavax, Inc., Johnson & Johnson Services, Inc., Lung Therapeutics Inc., Lupin Pharmaceuticals, Inc., Mallinckrodt PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Sanofi S.A, Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, Verona Pharma PLC, Vertex Pharmaceuticals Incorporated, Viatris Inc., and Wellona Pharma.
Inquire Before Buying @
Market Segmentation & Coverage:
This research report categorizes the Pulmonary Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:
Based on Drug Class, market is studied across Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines, Beta-2 Agonists, Combination Drugs, Monoclonal Antibodies, and Oral & Inhaled Corticosteroids. The Combination Drugs commanded largest market share of 21.23% in 2022, followed by Oral & Inhaled Corticosteroids.
Based on Indication, market is studied across Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, and Pulmonary Arterial Hypertension. The Chronic Obstructive Pulmonary Disease commanded largest market share of 25.09% in 2022, followed by Asthma.
Based on Drug Type, market is studied across Generic Drugs and Prescription Drugs. The Prescription Drugs commanded largest market share of 56.12% in 2022, followed by Generic Drugs.
Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Retail Pharmacies commanded largest market share of 74.59% in 2022, followed by Hospital Pharmacies.
Based on End-User, market is studied across Homecare, Hospitals, and Specialty Clinics. The Hospitals commanded largest market share of 39.23% in 2022, followed by Homecare.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 39.24% in 2022, followed by Asia-Pacific.
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Pulmonary Drugs Market, by Drug Class
7. Pulmonary Drugs Market, by Indication
8. Pulmonary Drugs Market, by Drug Type
9. Pulmonary Drugs Market, by Distribution Channel
10. Pulmonary Drugs Market, by End-User
11. Americas Pulmonary Drugs Market
12. Asia-Pacific Pulmonary Drugs Market
13. Europe, Middle East & Africa Pulmonary Drugs Market
14. Competitive Landscape
15. Competitive Portfolio
16. Appendix
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Pulmonary Drugs Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Pulmonary Drugs Market?
3. What is the competitive strategic window for opportunities in the Pulmonary Drugs Market?
4. What are the technology trends and regulatory frameworks in the Pulmonary Drugs Market?
5. What is the market share of the leading vendors in the Pulmonary Drugs Market?
6. What modes and strategic moves are considered suitable for entering the Pulmonary Drugs Market?
Read More @
Mr. Ketan Rohom
360iResearch
+1 530-264-8485
ketan@360iresearch
MENAFN10112023003118003196ID1107407198